Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

Stock Information for Kintara Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kintara Therapeutics Inc.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, CTLT, SCX, KTRA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, KTRA
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, KTRA, ABIO
KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA
Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law Firm
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Kintara Therapeutics, Inc. Merger
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIK, CHX, KTRA, ABIO

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.